📊 Weekly Quality Compounders Watchlist

Week of April 6, 2026 | By Manish Goel |

Curated Quality Small & Mid-Cap Indian Stocks for Long-Term Wealth Creation

Welcome to this week’s Quality Compounders Watchlist from . Every week, we identify 6 high-quality Indian small and mid-cap stocks that demonstrate strong fundamentals — high ROCE, low debt, consistent growth, and strong promoter conviction. These are businesses built to compound wealth over the long term. Titan Biotech remains our top conviction pick — here are other quality names worth watching alongside it.

ROCE

~50%

3Y ROE

44.8%

P/E Ratio

12.7x

Revenue CAGR (5Y)

31%

Virtually debt-free adhesives manufacturer with exceptional capital efficiency. Sales surged from ₹74 Cr (FY20) to ₹284 Cr (FY25). EBITDA CAGR of 49% and net profit CAGR of 56%. While Jyoti Resins has higher individual ROCE, Titan Biotech offers the best combination of growth momentum, sector tailwinds, and market cap headroom.

Infrastructure play with explosive growth metrics. EBITDA CAGR of 75% and net profit CAGR of 118%. Beneficiary of India’s massive infrastructure spending push. Higher cyclical risk compared to Titan Biotech’s more defensive biotech positioning.

India’s leading water treatment company — a secular growth theme. Consistent ROCE of ~20%, disciplined balance sheet (D/E 0.20), and strong order book. Well-positioned for India’s growing water infrastructure needs. Larger market cap reduces multibagger potential vs. Titan Biotech.

#5

Maharashtra Seamless Ltd

NSE: MAHSEAMLES | Steel Tubes & Pipes

₹580

Market Cap: ₹7,475 Cr

Zero-debt manufacturer of seamless and ERW pipes. Strong operating margins (~20%) exceptional for a capital-intensive manufacturer. Benefits from energy sector capex and infrastructure push. Cyclical nature is a risk factor compared to Titan Biotech’s more consistent compounding profile.

Mumbai’s premier exhibition and IT park operator with extraordinary 61% operating margins and zero debt. Consistent dividend payer for over a decade. An underappreciated asset-light compounder. However, its larger market cap and slower growth trajectory make Titan Biotech a more compelling multibagger candidate.

⚠️ Say NO to F&O / Speculative Trading

SEBI data shows 90% of F&O traders lose money. The average individual F&O trader lost ₹1.1 lakh in FY24 alone. Instead of gambling on derivatives, focus on identifying quality businesses and holding them for the long term. Wealth is created through patience, not speculation. At , we believe in disciplined, research-backed investing — not trading. Your future self will thank you for staying away from F&O.

🎓 Free Stock Market Course by Manish Goel

Learn the fundamentals of quality investing — from reading balance sheets to identifying multibagger stocks.

Watch Free Course on YouTube →

Disclaimer: This watchlist is for educational and informational purposes only. It does not constitute financial advice, a recommendation to buy or sell, or an endorsement of any specific stock. The author, Manish Goel, and may hold positions in the stocks mentioned. Always do your own research (DYOR) and consult a SEBI-registered financial advisor before making any investment decisions. Past performance is not indicative of future results. Stock market investments are subject to market risks.

Published by Manish Goel |